Kevin Carey, DO
Family Medicine · Plains, PANPI 1477643294
Payments from drug & device makers
Across 957 payments — averaging $13.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Novo Nordisk$2K
- AstraZeneca$1K
- AbbVie$1K
- Lilly USA, LLC$1K
- Amgen$1K
- plus $5K from 34 others
What the payments were for
- Food & beverage$12,71499%
- Education$1411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 157 | $1,747 |
| Novo Nordisk | 130 | $1,662 |
| AstraZeneca | 70 | $1,342 |
| AbbVie(2 entities) | 70 | $1,117 |
| Lilly USA, LLC | 94 | $1,094 |
| Amgen | 85 | $1,057 |
| Boehringer Ingelheim | 51 | $666 |
| Kowa Pharmaceuticals America, Inc. | 35 | $411 |
| Astellas Pharma US Inc | 18 | $377 |
| Pfizer | 31 | $336 |
| Shield Therapeutics Inc | 22 | $329 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $327 |
| Esperion Therapeutics, Inc. | 25 | $301 |
| Amarin Pharma, Inc. | 28 | $300 |
| E.r. Squibb & Sons, L.L.C. | 15 | $227 |
| Exact Sciences | 12 | $207 |
| Dexcom, Inc. | 10 | $161 |
| Phathom Pharmaceuticals, Inc. | 11 | $158 |
| Abbott | 9 | $141 |
| Merck | 8 | $94 |
| Biogen | 7 | $88 |
| Novartis | 5 | $84 |
| Axsome Therapeutics, Inc. | 5 | $82 |
| Radius Health, Inc. | 5 | $79 |
| Eisai Inc. | 3 | $57 |
| Sumitomo Pharma America, Inc. | 3 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $42 |
| Bayer | 3 | $41 |
| GSK | 2 | $40 |
| Tactile Systems Technology Inc | 2 | $39 |
| Lundbeck LLC | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| QOL Medical, LLC | 2 | $26 |
| Biotronik NRO, Inc. | 1 | $25 |
| Boston Scientific | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Endogastric Solutions, Inc | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,855 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 113 | $119,132 |
| OzempicSemaglutide | 96 | $116,736 |
| EliquisApixaban | 121 | $96,626 |
| XareltoRivaroxaban | 62 | $71,115 |
| TradjentaLinagliptin | 35 | $47,317 |
| MyrbetriqMirabegron | 51 | $44,108 |
| FarxigaDapagliflozin Propanediol | 37 | $29,332 |
| TrulicityDulaglutide | 28 | $26,899 |
| WegovySemaglutide | 18 | $23,720 |
| EntrestoSacubitril/Valsartan | 29 | $23,125 |
| ProliaDenosumab | 13 | $22,037 |
| LinzessLinaclotide | 18 | $17,709 |
| MounjaroTirzepatide | 12 | $12,018 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $10,586 |
| Rosuvastatin Calcium | 510 | $8,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $666 | $166,448148 claims |
| Novo NordiskOzempic, Wegovy | $1,662 | $140,456114 claims |
| PfizerEliquis | $336 | $96,626121 claims |
| Johnson & JohnsonXarelto | $1,747 | $71,11562 claims |
| Astellas Pharma US IncMyrbetriq | $377 | $44,10851 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,094 | $38,91740 claims |
| AstraZenecaFarxiga | $1,342 | $29,33237 claims |
| NovartisEntresto | $84 | $23,12529 claims |
| AmgenProlia | $1,057 | $22,03713 claims |
| AbbVieLinzess, Synthroid | $1,117 | $19,63072 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Plains
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.